



SECOND-QUARTER 2024 RESULTS

TOTAL COMPANY

\$10.4B **+9.3%**¹

SALES
WORLDWIDE

Organic* sales growth for
underlying base business**


\$1.14²

ADJUSTED DILUTED EPS

BUSINESS HIGHLIGHTS

BREAKTHROUGH INNOVATION IN PERIPHERAL ARTERY DISEASE

- ▶ FDA approval of the Esprit™ below-the-knee (BTK) system.
- ▶ System is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving.



ESPRIT™
BTK SYSTEM

KEY BUSINESS UNITS³



12.1%
MEDICAL DEVICES



5.9%
DIAGNOSTICS
Excludes the impact of
COVID-19 testing sales



8.1%
ESTABLISHED
PHARMACEUTICALS



7.5%
NUTRITION

EXPANDING IN BIOWEARABLES

- ▶ FDA clearance for two new over-the-counter continuous glucose monitoring systems: Lingo™ and Libre Rio™.
- ▶ Systems are based on Abbott's world-leading FreeStyle Libre®™ continuous glucose monitoring technology.



RAISED FULL-YEAR GUIDANCE

\$4.61 to \$4.71⁴

ADJUSTED DILUTED EPS

9.5% to 10.0%⁵

ORGANIC SALES GROWTH
Excluding COVID-19 testing-related sales

PIONEERING CARDIAC CARE

- ▶ CE Mark for AVEIR™ DR Dual Chamber Leadless Pacemaker System.
- ▶ AVEIR DR Leadless Pacemaker System is the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.

AVEIR DR DUAL
CHAMBER LEADLESS
PACEMAKER SYSTEM



*Organic sales growth excludes impact of foreign exchange, the impact of discontinuing the ZonePerfect® product line in the Nutrition business, and the impact of the acquisition of Cardiovascular Systems, Inc. during the first year post-acquisition. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 18, 2024, available at www.abbottinvestor.com.

**Excludes the impact of COVID-19 testing sales.

***Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

1. On a GAAP basis, second-quarter 2024 Abbott sales increased 4.0%. 2. Second-quarter GAAP diluted EPS was \$0.74. 3. On a GAAP basis, second-quarter 2024 Medical Devices sales increased 10.2%, Established Pharmaceuticals sales increased 0.6%, Nutrition sales increased 3.5% and Diagnostics sales decreased 5.3%. 4. Abbott projects full-year 2024 diluted earnings per share under GAAP of \$3.30 to \$3.40. Abbott forecasts specified items for the full-year 2024 of \$1.31 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be \$4.61 to \$4.71 for the full-year 2024. 5. Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.